Ellen M. Mowry
Johns Hopkins University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Ellen M. Mowry as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:01 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07497399 · Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple SclerosisJohns Hopkins University · recruiting · Multiple Sclerosis
- N/ANCT03500328 · Traditional Versus Early Aggressive Therapy for Multiple Sclerosis TrialJohns Hopkins University · completed · Multiple Sclerosis, Relapsing-Remitting · principal investigator
- Ph1NCT02253264 · A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis PatientsJohns Hopkins University · completed · Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
- N/ANCT01667796 · Pharmacokinetics of Vitamin D in Multiple Sclerosis and in HealthJohns Hopkins University · completed · Multiple Sclerosis, Relapsing-remitting
- Ph3NCT01490502 · Vitamin D Supplementation in Multiple SclerosisJohns Hopkins University · completed · Relapsing Remitting Multiple Sclerosis
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:01 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Home-based actigraphy to predict disability progression and enhance clinical trials in multiple sclerosisR01NR018851 · NINR · JOHNS HOPKINS UNIVERSITY · fiscal years 2020 to 2026 · $777,492 awarded in 2026Same name and institution; not confirmed by an ID
- The effect of vitamin D on the clinical and imaging course of multiple sclerosisK23NS067055 · NINDS · JOHNS HOPKINS UNIVERSITY · fiscal years 2010 to 2014 · $193,023 awarded in 2014Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:01 UTC. The ranking covers the 200 most relevant of 14 PubMed records, and a shared surname and initials can bring in a namesake. All 14 on PubMed
- Effect of intermittent vs. daily calorie restriction on changes in weight and patient-reported outcomes in people with multiple sclerosis.Mult Scler Relat Disord · 2018120 citationsRCR 5.3
- 119 citationsRCR 13.8
- Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis.Neurology · 2016108 citationsRCR 4.5
- Metabolic alterations in multiple sclerosis and the impact of vitamin D supplementation.JCI Insight · 201797 citationsRCR 3.7
- Intermittent calorie restriction alters T cell subsets and metabolic markers in people with multiple sclerosis.EBioMedicine · 202260 citationsRCR 4.9
- The vitamin D to ameliorate multiple sclerosis (VIDAMS) trial: study design for a multicenter, randomized, double-blind controlled trial of vitamin D in multiple sclerosis.Contemp Clin Trials · 201456 citationsRCR 2.0
- Safety and feasibility of various fasting-mimicking diets among people with multiple sclerosis.Mult Scler Relat Disord · 202027 citationsRCR 1.4
- Magnetic resonance imaging correlates of clinical outcomes in early multiple sclerosis.Mult Scler Relat Disord · 201426 citationsRCR 1.0
- Demographics and baseline disease characteristics of Black and Hispanic patients with multiple sclerosis in the open-label, single-arm, multicenter, phase IV CHIMES trial.Mult Scler Relat Disord · 202313 citationsRCR 1.6
- 7 citationsRCR 0.7